Alfacalcidol

Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis[1][2][3][4].

Product Specifications

CAS Number

[41294-56-8]

Product Name Alternative

1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3

UNSPSC

12352211

Hazard Statement

H300

Target

VD/VDR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Alfacalcidol.html

Purity

99.96

Solubility

DMSO : ≥ 50 mg/mL

Smiles

C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CCCC(C)C)C)CCC/2)[H])O)O

Molecular Formula

C27H44O2

Molecular Weight

400.64

Precautions

H300

References & Citations

[1]Galeşanu C, et al. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110 (4) :833-41.|[2]Nuijten M, et al. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clin Drug Investig. 2010;30 (8) :545-57.|[3]Shiraishi A, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65 (4) :311-6.|[4]Nagaoka H, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32 (8) :1030-6.